ADC Therapeutics reported a gross margin of 89.07% and a net margin of -86.06% for the quarter ended Jun 2026. These financial ratios cover 26 quarters of results from Mar 2020 through Jun 2026, standardized by Business Quant from the company’s SEC filings.
| Ratios | Mar2020 | Jun2020 | Sep2020 | Dec2020 | Mar2021 | Jun2021 | Sep2021 | Dec2021 | Mar2022 | Jun2022 | Sep2022 | Dec2022 | Mar2023 | Jun2023 | Sep2023 | Dec2023 | Mar2024 | Jun2024 | Sep2024 | Dec2024 | Mar2025 | Jun2025 | Sep2025 | Dec2025 | Mar2026 | Jun2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Profitability | ||||||||||||||||||||||||||
| Gross Margin | 96.18% | 98.86% | 86.89% | 98.30% | 96.89% | 93.16% | 97.47% | 86.10% | 93.01% | 95.39% | 91.05% | 95.56% | 92.68% | 83.37% | 89.07% | |||||||||||
| EBT Margin | -543.12% | -38.35% | -377.77% | -67.24% | -314.28% | -273.30% | -313.27% | -253.70% | -205.13% | -236.24% | -166.88% | -294.03% | -249.38% | -158.11% | -86.06% | |||||||||||
| EBIT Margin | -439.58% | -86.81% | -401.43% | -4.08% | -271.55% | -205.62% | -249.42% | -186.19% | -166.81% | -192.61% | -123.58% | -234.34% | -188.52% | -121.07% | -132.03% | |||||||||||
| EBITDA Margin | -439.58% | -86.81% | -401.43% | -4.08% | -271.55% | -205.62% | -249.42% | -186.19% | -166.81% | -192.61% | -123.58% | -234.34% | -188.52% | -121.07% | -132.03% | |||||||||||
| Operating Margin | -439.58% | -86.81% | -401.43% | -4.08% | -271.55% | -205.62% | -249.42% | -186.19% | -166.81% | -192.61% | -123.58% | -234.34% | -188.52% | -121.07% | -132.03% | |||||||||||
| Net Margin | -544.22% | -35.83% | -372.30% | -66.31% | -312.90% | -249.96% | -312.58% | -254.81% | -206.47% | -236.73% | -167.59% | -300.68% | -249.38% | -158.11% | -86.06% | |||||||||||
| FCF Margin | -456.32% | -73.36% | -306.86% | 2.62% | -86.39% | -187.73% | -257.60% | -247.19% | -188.83% | -136.80% | -245.73% | -127.86% | -180.37% | -142.64% | -61.34% | |||||||||||
| Efficiency | ||||||||||||||||||||||||||
| Inventory AverageInventory Avg. | 7.86M | 9.56M | 11.48M | 13.24M | 15.20M | 13.91M | 15.16M | 18.84M | 21.08M | 19.45M | 16.09M | 15.59M | 15.63M | 9.16M | 9.85M | 17.61M | 17.90M | 11.11M | 4.48M | 4.85M | ||||||
| Assets AverageAssets Avg. | 551.18M | 627.98M | 599.93M | 551.17M | 526.11M | 511.31M | 479.27M | 487.49M | 487.10M | 410.84M | 331.37M | 339.87M | 360.43M | 335.53M | 297.26M | 297.05M | 305.66M | 306.45M | 307.32M | 285.44M | ||||||
| Invested CapitalInvested Cap. | 247.75M | 257.63M | 211.76M | 214.11M | 152.50M | 105.50M | 62.12M | -35.52M | -81.22M | -17.97M | -57.75M | -89.01M | -124.40M | -84.68M | -122.98M | -70.38M | -100.70M | -111.57M | ||||||||
| Asset Utilization RatioAsset Util. | 0.03 | 0.11 | 0.15 | 0.29 | 0.33 | 0.27 | 0.27 | 0.21 | 0.20 | 0.19 | 0.26 | 0.26 | 0.25 | 0.26 | 0.26 | |||||||||||
| Leverage & Solvency | ||||||||||||||||||||||||||
| Interest Coverage RatioInterest Cover | -13.55 | -4.38 | -7.89 | -0.27 | -4.95 | -3.85 | -2.82 | -2.69 | -2.29 | -2.71 | -2.33 | -3.40 | -2.31 | -2.04 | -1.88 | |||||||||||
| Debt Ratio | 0.14 | 0.15 | 0.16 | 0.19 | 0.23 | 0.27 | 0.27 | 0.25 | 0.27 | 0.32 | 0.37 | 0.31 | 0.33 | 0.35 | 0.42 | 0.36 | 0.40 | 0.36 | 0.40 | 0.42 | ||||||
| Times Interest Earned | -13.55 | -4.38 | -7.89 | -0.27 | -4.95 | -3.85 | -2.82 | -2.69 | -2.29 | -2.71 | -2.33 | -3.40 | -2.31 | -2.04 | -1.88 | |||||||||||
| Valuation | ||||||||||||||||||||||||||
| Price to EarningsP/E | -29.12 | -67.72 | -9.49 | -7.32 | -2.92 | -3.97 | -1.77 | -8.08 | -8.48 | -6.97 | -3.62 | -5.32 | -11.00 | -14.46 | -8.23 | |||||||||||
| Price to SalesP/S | 158.50 | 24.27 | 35.32 | 4.85 | 9.14 | 9.93 | 5.53 | 20.59 | 17.51 | 16.50 | 6.07 | 16.00 | 27.42 | 22.87 | 7.08 | |||||||||||
| Price to BookP/B | 10.07 | 6.94 | 5.29 | 3.90 | 6.11 | -9.72 | -1.25 | -0.92 | -1.91 | -2.32 | -1.77 | -0.97 | -0.59 | -1.51 | -1.89 | -2.39 | -2.20 | -0.60 | ||||||||
| Enterprise Value | 1,553.56M | 1,085.03M | 697.47M | 233.87M | -10.63M | -16.77M | -136.92M | -156.07M | -230.27M | -141.99M | 137.37M | 4.73M | 30.27M | -54.13M | -54.86M | 36.94M | 215.77M | 182.56M | 245.86M | -82.75M | ||||||
| EV to EBIT | -26.88 | -17.28 | -3.37 | 3.41 | 2.65 | 3.94 | 6.37 | -4.09 | -0.16 | -0.85 | 1.93 | -0.84 | -6.97 | -9.74 | 3.26 | |||||||||||
| EV to EBITDA | -26.88 | -17.28 | -3.37 | 3.41 | 2.65 | 3.94 | 6.37 | -4.09 | -0.16 | -0.85 | 1.93 | -0.84 | -6.97 | -9.74 | 3.26 | |||||||||||
| Market Capitalization | 2,083.76M | 1,551.57M | 1,128.35M | 610.64M | 370.23M | 309.67M | 173.63M | 191.44M | 80.14M | 136.61M | 371.67M | 304.84M | 304.57M | 196.73M | 139.84M | 301.50M | 450.51M | 443.89M | 476.87M | 136.36M | ||||||
| Price to FCFP/FCF | -34.73 | -25.00 | -33.08 | -11.51 | 185.02 | -5.75 | -10.58 | -5.29 | -2.15 | -4.27 | -8.33 | -9.27 | -12.06 | -8.97 | -2.47 | -12.52 | -15.20 | -14.26 | -16.03 | -11.55 | ||||||
| EV to FCF | -25.90 | -17.49 | -20.45 | -4.41 | -5.31 | 0.31 | 8.34 | 4.31 | 6.17 | 4.44 | -3.08 | -0.14 | -1.20 | 2.47 | 0.97 | -1.53 | -7.28 | -5.87 | -8.27 | 7.01 | ||||||
| EV to CFO | -26.52 | -17.61 | -20.59 | -4.41 | -4.84 | 0.31 | 8.90 | 4.46 | 6.28 | 4.49 | -3.12 | -0.14 | -1.21 | 2.48 | 0.97 | -1.53 | -7.28 | -5.87 | -8.28 | 7.01 | ||||||
| Return Ratios | ||||||||||||||||||||||||||
| Return on Sales [ROS]ROS | -439.58% | -86.81% | -401.43% | -4.08% | -271.55% | -205.62% | -249.42% | -186.19% | -166.81% | -192.61% | -123.58% | -234.34% | -188.52% | -121.07% | -132.03% | |||||||||||
| Return on Capital Employed [ROCE]ROCE | -51.10% | -45.22% | -49.85% | -38.92% | -41.30% | -40.24% | -31.91% | -59.98% | -49.05% | -45.90% | -52.90% | -59.03% | -57.12% | -53.75% | -63.17% | |||||||||||
| Return on Invested Capital [ROIC]ROIC | -94.40% | -100.65% | -88.29% | -123.38% | -151.54% | 269.50% | 272.70% | 355.81% | 119.22% | 132.58% | 135.14% | 151.87% | 119.52% | |||||||||||||
| Return on Assets [ROA]ROA | -39.18% | -35.39% | -40.85% | -38.62% | -39.87% | -45.66% | -41.79% | -60.03% | -51.62% | -47.43% | -55.26% | -58.88% | -58.86% | -55.05% | -51.55% |